CN106581591A - Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases - Google Patents
Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases Download PDFInfo
- Publication number
- CN106581591A CN106581591A CN201710104507.5A CN201710104507A CN106581591A CN 106581591 A CN106581591 A CN 106581591A CN 201710104507 A CN201710104507 A CN 201710104507A CN 106581591 A CN106581591 A CN 106581591A
- Authority
- CN
- China
- Prior art keywords
- miao
- parts
- pharmaceutical composition
- application
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to application of drug composition in preparation of drugs for treating a cerebrovascular disease or relevant diseases. The drug composition is prepared from authentic Miao national herbs coptis chinensis (named as wanglianjin in Miao language), manyinflorescaned sweetvetch root (named as douxiao in Miao language), rhizoma rehmanniae (named as feita in Miao language), turmeric (named as woha in Miao language) and scutellaria baicalensis (named as ega in Miao language) and is applied to treatment of dizziness caused by stroke, apoplexy sequela, local anemia, bleeding, edema after bleeding, reperfusion injury, thrombus, vasoconstriction, obstruction, Alzheimer's disease and various causes. In addition, it is proved through an animal experiment that the drug composition has the treating effect on the cerebrovascular disease or the relevant diseases and has the effect of regulating a physical function, and another choice is provided for a patient.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition is preparing the treatment cerebrovascular or the application in relevant disease medicine.
Background technology
The coptis, Miao is Wabge leenc naemx (transliteration be Wang Lian stems), belongs to perennial herb, with heat-clearing and damp-drying drug,
The effect of purging intense heat and detonicating；Nature and flavor are bitter, cold；The thoughts of returning home, spleen, stomach, liver, courage, large intestine channel；It is mainly used in damp and hot feeling of fullness, vomits acid regurgitation, rushes down
Dysentery, jaundice, unconsciousness due to high fever, heart-fire hyperactivity, dysphoria and insomnia, blood-head tells nosebleed, hot eyes, toothache is quenched one's thirst, carbuncle swells furunculosis；Eczema is controlled outward,
Wet sore, duct is suppurated；The card of endoretention of damp heat can be controlled with the root of large-flowered skullcap, rheum officinale etc.；Rush down dysentery can be controlled with the banksia rose, the root of large-flowered skullcap, root of kudzu vine etc.；Coordinate day
Pollen, the wind-weed, glutinous rehmannia etc. can control in exuberance of stomach fire the card that disappears.
Red stilbene, Miao is Dout hxaok (transliteration is confused for beans), is the dry root of legume Hedysarum polybotrys Hand.-Mazz, with benefit
Superficies-consolidating, diuretic and maintain drug, apocenosis, the effect of expelling pus and promoting granulation；Nature and flavor are sweet, temperature；Return lung, the spleen channel；It is mainly used in treatment deficiency of vital energy weak, deficiency of food is just
It is half congealed, the sinking of qi of middle-jiao, rush down prolapse of the anus for a long time, uterine bleeding of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy oedema, ulcer is difficult to burst, blood deficiency chlorosis, Heat Diabetes, slowly
Property nephritic proteinuria, diabetes.
Glutinous rehmannia, Miao is Hfeex dab (transliteration for fertile clatter), is Scrophulariaceae herbaceos perennial, with clearing heat and promoting fluid,
Cool blood, the effect of hemostasis；Nature and flavor are sweet, bitter, cold；The thoughts of returning home, liver and kidney channel；It is mainly used in consumption of YIN caused by febrile disease, the deep red polydipsia of tongue, spot dermexanthesis are told
Blood, bleeding from five sense organs or subcutaneous tissue, abscess of throat.
Turmeric, Miao is Voh had (transliteration breathe out for nest), is herbaceos perennial, with blood-breaking, inducing meastruation to relieve menalgia
Effect；Nature and flavor temperature, pungent, hardship；Return liver, the spleen channel；It is mainly used in chest side of body to twinge, amenorrhoea ， wei lumps in the abdomen, rheumatism shoulder arm pain, tumbling and swelling；
In terms of pharmacology, its contain reducing blood lipid, antitumor, anti-inflammatory, resisting pathogenic microbes, cholagogic, terminal pregnancy, antioxidation into
Point.The coptis, Chinese cassia tree, corydalis tuber, RADIX CURCUMAE etc. is coordinated to control vexed gastritis, cholangitis, abdominal distension, pain, vomiting, jaundice.
The root of large-flowered skullcap, Miao is Hgeil ghab (transliteration is volume loud, high-pitched sound), with heat-clearing and damp-drying drug, the effect of purging intense heat and detonicating；Nature and flavor hardship,
It is cold；Return lung, courage, spleen, large intestine, small intestinl channel；It is mainly used in damp-warm syndrome, heat temperature evil of vomitting uncomfortable in chest, damp and hot feeling of fullness, rush down dysentery, jaundice, lung heat is coughed
Cough, hyperpyrexia polydipsia, blood-head tells nosebleed, carbuncle sore tumefacting virus, fetal irritability；Clinically, the coptis, cape jasmine etc. is coordinated to control pyreticosis hyperpyrexia；With
The dried rhizome of rehmannia, moutan bark, the primary leaf equivalent use in side can control blood-heat bleeding.
Above-mentioned medicinal material southwest belong to authentic medicinal herbs, be also Guizhou, Chongqing locality ethnic group especially Miao ethnic group commonly use
Seedling medicine, at present, there is not yet 5 kinds of medicinal materials such as the coptis, red stilbene, glutinous rehmannia, turmeric and root of large-flowered skullcap are provided commonly for treat the cerebrovascular and phase
The report of related disorders.Cerebrovascular disease as clinical common critical illness, its have " incidence of disease is high, the death rate is high, disability rate is high,
High recurrence rate, complication are more " the characteristics of；Based on medical development and spirit of seeking knowledge, using Chinese medicine the cerebrovascular and related disease are prevented and treated
The application of disease is explored.
Such as Patent No. 201010541220.7,《A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease》, its composition is：Stone
Calamus, the red sage root, the seed of Oriental arborvitae, polygala root, the tuber of dwarf lilyturf, fushen, cattail pollen, tortoise plastron, keel, purslane, the dried rhizome of rehmannia, deer horn, wilsonii, river
Rhizome of chuanxiong, the coptis, golden cypress, the tuber of pinellia, corydalis tuber, turmeric, Radix Angelicae Sinensis, radix bupleuri, spina date seed, the Radix Astragali, the root of bidentate achyranthes, the root of herbaceous peony, earthworm, ginseng, teasel root,
Mulberry leaf, sealwort, cultivated land, curcuma zedoary, cassia seed, Polygonum multiflower knotweed, motherwort, pubeseent epimedium herb, the rhizome of davallia, the banksia rose, rhizoma atractylodis, Rhizoma Atractylodis Macrocephalae preparata, Fructus Aurantii,
Giant knotweed, dried orange peel, hairyvein agrimony, purple perilla, oriental wormwood, pearl.
And for example Patent No. 201010242326.7,《A kind of Chinese medicine composition and its preparation method and application》, its raw material
Including：Red stilbene, sun-dried ginseng, the bighead atractylodes rhizome, Poria cocos, sealwort, coix seed, RADIX POLYGONI MULTIFLORI PREPARATA, HERBA EPIMEDII, deer horn glue, tortoise plastron, saline cistanche, mountain cornel
Meat, the fruit of Chinese wolfberry, Radix Angelicae Sinensis, the root of herbaceous peony, the red sage root, Ligusticum wallichii, reticulate millettia, Radix Rhapontici seu Radix Echinopsis, scorpio, centipede and Radix Glycyrrhizae, also disclose the raw material group
Application of the compound in the medicine for preparing apoplexy sequela.
As cerebrovascular patients increase, the research of its medicine is also more and more more, but cure rate is still undesirable,
The report of remarkable result is also less, and disability person accounts for 75% in survival crowd, therefore, the medicine of cranial vascular disease
Research also needs further to further investigate, and the applicant is by the adaptation shared to the coptis, red stilbene, glutinous rehmannia, turmeric and the root of large-flowered skullcap
When illness is studied, it has unexpectedly been found that, this kind of combination also has significantly treatment in terms of the treatment cerebrovascular and relevant disease
Effect.
The content of the invention
It is an object of the invention to provide in pharmaceutical composition made by with the coptis, red stilbene, glutinous rehmannia, turmeric, the root of large-flowered skullcap as raw material
Prepare treatment the cerebrovascular or cerebrovascular relevant disease medicine in application, also provide its prepare treatment Alzheimer disease,
Improve the application in Rats With Memory medicine.
The cerebrovascular of the present invention is ischemic cerebrovascular disease, hemorrhagic cerebrovascular disease；Specially：The cranial vascular disease
For：Oedema, cerebral ischemia/reperfusion injury, cerebral thrombus, infraction, nmda receptor induction after Prognosis of Acute Intracerebral Hemorrhage, cerebral ischemia, ischemic
Cranial nerve cell is damaged.；
Cerebrovascular relevant disease of the present invention includes what Alzheimer's and vertebral-basilar artery insufficiency were caused
Dizziness；
Pharmaceutical composition of the present invention, by weight, the raw material for making the pharmaceutical composition active principle is：The coptis
(Miao：Wang Lian stems) 266-288 parts, red stilbene (Miao：Beans confuse) 800-864 parts, glutinous rehmannia (Miao：Fertile clatter) 800-864 parts, turmeric
(Miao：Nest is breathed out) 800-864 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 532-576 parts；
Preferred proportioning is：The coptis (Miao：Wang Lian stems) 270-283 parts, red stilbene (Miao：Beans confuse) 810-849 parts, glutinous rehmannia
(Miao：Fertile clatter) 810-849 parts, turmeric (Miao：Nest is breathed out) 810-849 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 540-566 parts；
Most preferably proportioning is：The coptis (Miao：Wang Lian stems) 277 parts, red stilbene (Miao：Beans confuse) 833 parts, glutinous rehmannia (Miao：
Fertile clatter) 833 parts, turmeric (Miao：Nest is breathed out) 833 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 555 parts；
The pharmaceutical composition that the present invention is provided, its preparation method is：
(1) raw material is weighed, it is standby；
(2) coptis, turmeric, plus ethanol immersion, heating and refluxing extraction are taken, is merged, filtration, reclaim ethanol, concentration is standby；
(3) step 2 is taken) gained filter residue, decoct after soaking with red stilbene, glutinous rehmannia, merge, decocting liquid filtration, filtrate stands,
Filtration, filtrate and step 2) gained liquid merges, and is condensed into clear cream, filtration, and filtrate adds Steviosin, standby；
(4) root of large-flowered skullcap is taken, plus ethanol immersion, heating and refluxing extraction, merging, ethanol is reclaimed in extract filtration, is condensed into clear
Cream, filtration, filtrate adds Steviosin, standby；
(5) said extracted thing is merged, is fully mixed, obtained final product.
Specifically, pharmaceutical composition of the present invention, its preparation method is：
(1) raw material is weighed, it is standby；
(2) coptis, turmeric are taken, plus ethanol immersion 1h, heating and refluxing extraction 3 times, wherein, the 1st extraction time is 1h, the
2nd, 3 extraction times be 50min, merge extract, ethanol is reclaimed in filtration, is concentrated into relative density for 1.00-1.05 (60
DEG C), it is standby；
(3) step 2 is taken) gained filter residue, 1h is soaked with red stilbene, glutinous rehmannia, decoct 2 times, wherein, the 1st decocting time
For 1.3h, the 2nd decocting time is 1h, and collecting decoction is filtered, and filtrate stands 24h, filtration, filtrate and step 2) gained liquid conjunction
And, the clear cream that relative density is 1.15-1.20 (60 DEG C) is concentrated into, filtration adds in filtrate and accounts for composition material gross weight 0.4-
0.5% Steviosin, it is standby；
(4) root of large-flowered skullcap plus ethanol immersion 1h are taken, heating and refluxing extraction 2 times, wherein, the 1st extraction time is 2h, is carried for the 2nd time
The time is taken for 1.6h, merges extract, ethanol is reclaimed in filtration, be concentrated into the clear cream that density is 1.15-1.20 (60 DEG C), filtration,
Filtrate adds the Steviosin for accounting for composition material gross weight 0.07-0.1%, standby；
(5) said extracted thing is merged, is fully mixed, obtained final product.
Preferably, in the preparation method, step 2) ethanol be ethanol solution that volumetric concentration is 60%；
Preferably, the step 3) Steviosin that adds, its consumption accounts for composition material gross weight 0.46%；
It is highly preferred that the step 4) Steviosin that adds, its consumption accounts for composition material gross weight 0.09%；
The pharmaceutical composition of the present invention can as needed add one or more pharmaceutically acceptable carrier, such as dilute
Agent, excipient, filler, disintegrant, wetting agent, adhesive, surfactant, sorbefacient, lubricant etc., according to pharmacy
The conventional method in field, is prepared into required formulation；
Medicine of the present invention is ejection preparation, tablet, pill, capsule, granule, oral liquid, pill；
Preferably granule；
With the pharmaceutical composition that the cerebrovascular or relevant disease are treated obtained in the inventive method, according to clinical verification, as a result show
Show pharmaceutical composition of the present invention with the effect such as treatment cerebrovascular disease and the dizziness caused by relevant diseases such as cerebral ischemics, tool
Say, the pharmaceutical composition that the present invention is provided is damaged to oedema, Cerebral Ischemia/Reperfusion after Prognosis of Acute Intracerebral Hemorrhage, cerebral ischemia, ischemic body
Determined curative effect, the security of wound, cerebral thrombus, infraction, nmda receptor induction cranial nerve cell damage, Alzheimer's etc.
Well, quality controllability height, and extracting method is simple, process stabilizing, is adapted to batch production, meanwhile, also with active ingredient
Content is higher, and bioavilability is high, the characteristics of evident in efficacy.
In order that those skilled in the art more fully understand the present invention, it is expanded on further below by way of experiment and embodiment
The composition of pharmaceutical composition of the present invention, Preparation method and use：
1st, the clinical observation test of medicine composite for curing focal cerebral ischemia of the present invention
1.1 material：
1.1.1 medicine：
Invention formulation：Particle obtained in embodiment 14.
Control medicine：Brain pacifies particle；Specification：Per packed 1.2g；Bai Quan pharmaceutical Co. Ltds of Henan Province produce.
1.1.2 subjects：Healthy rat (body weight about 250g), equal male and female half and half.
1.2 test method
1.2.1 test method：50 healthy adult rats are selected, 5 groups are divided at random：Blank control group, brain peace particle
1,2 groups of administration, embodiment 14 is administered 1,2 groups, once a day, is administered three days, wherein, blank control group physiological saline gavage,
Respectively with 50.0mg/kg, 60.0mg/kg dosed administration, embodiment 14 is administered 1,2 groups of difference to 1,2 groups of brain peace particle dosed administration
With 50.0mg/kg, 40.0mg/kg dosed administration.
1.2.2 the foundation of animal model：Electricity consumption inustion blocking rat side arteria cerebri media (MCAO), causes focal
Cerebral ischemia.It is postoperative to give feed water inlet.
1.2.3 observation index：
1.2.3.1 the measure of brain infarction area：Postoperative 24h broken ends take brain, and the coronal brain piece for being cut to 0.3cm, observation whether there is
Hemorrhagic focus.Brain piece is immersed in TTC dyeing liquors, lucifuge incubates 30min in the middle temperature of 37 DEG C of water-baths, take out brain piece and be put into 10% formal
Fixed in woods, normal structure is in rose, and ischemic tissue is white；Infarct size is measured with the weight method of quadrature, infarcted region is calculated
Domain accounts for the percentage of full brain.
1.2.3.2 the measure of brain water content：Brain water content is determined with wet-dry change, at animal after death, full brain is taken out, removal is smelt
Brain, low brain stem and cerebellum, weigh immediately brain weight in wet base, are placed in 180 DEG C of oven for baking to constant weight, and brain stem weight is weighed after 18h；
Brain water content (%)=(1- brain stem weight/brain weight in wet bases) × 100%.
1.2.3.3 pathology detection：After brain piece is dyed, histopathology change is observed under an optical microscope.
1.3 result
1.3.1 the measurement result of focal cerebral ischemia in rats 24h cerebral infarction area, as shown in table 1：
The Brain stem injury of table 1
| Group | Number of cases | Infarct size (%) |
| Blank control group | 10 | 11.12±2.08 |
| Brain pacifies 1 group of particle delivery | 10 | 5.89±2.15* |
| Brain pacifies 2 groups of particle delivery | 10 | 5.66±1.50* |
| Embodiment 14 is administered 1 group | 10 | 5.02±1.33* |
| Embodiment 14 is administered 2 groups | 10 | 5.18±1.71* |
Note：Administration group compares * P with control group<0.05
Conclusion：The brain infarction area of administration group is significantly lower than between control group, and group without the significance difference opposite sex.Prove medicine of the present invention
Compositions can reduce the brain infarction area of cerebral ischemia animal.
1.3.2 after focal cerebral ischemia in rats 24h brain water content measurement result, as shown in table 2：
The brain water content of table 2
Note：Administration group compares * P with control group<0.05, * * P<0.01
Conclusion：The brain water content of administration group is significantly lower than between control group, and group without the significance difference opposite sex.Prove medicine of the present invention
Composition can substantially mitigate ischemic brain edema.
1.3.3 pathological change：Control group light Microscopic observation, it is found that tissue space is broadening, and oedema has vacuolization, god
Jing units nucleus reduces, or even dissolving disappears.And treatment group can see that tissue space oedema is light compared with control group, space between cells changes
Become not substantially, neuronal cell core size is normal, and core contaminates more deeply, and there is a little vacuolization in lesion center area.
2nd, the clinical observation test of medicine composite for curing platelet thrombosis of the present invention
2.1 trial drug：Embodiment 6, embodiment 15, preparation obtained in embodiment 16.
2.2 subjects：Healthy rat (body weight about 250g), equal male and female half and half.
2.3 test method：Select 40 healthy adult rats, be divided into 4 groups at random, experimental group give respectively embodiment 6,
Embodiment 15, each 50mg/kg of embodiment 16, once a day, continuous 7 days, blank control group gave the physiological saline of equivalent, last
Anaesthetize after administration 1h, it is fixed, tracheae insertion tracheal catheter is separated, separate RCCA and left vena jugularis externa；In polyethylene pipe
It is secondary to be put into a silk thread weighed, polyethylene pipe is full of with the physiological saline containing heparin, right neck is inserted in one end of pipe and is always moved
Arteries and veins, the other end inserts left vena jugularis externa.Open and interrupt after blood flow 15min, take out silk thread and weigh, calculate thrombus weight.
2.4 result of the tests, as shown in table 3：
The thrombus weight of table 3
Note：Administration group compares * P with control group<0.05
Conclusion：This pharmaceutical composition has suppression thrombotic effect in vivo.
3rd, pharmaceutical composition of the present invention induces nmda receptor the impact test that cranial nerve cell is damaged
3.1 trial drug：Embodiment 6, preparation obtained in embodiment 16.
3.2 subjects：Male rat (body weight about 250g).
3.3 test method：
3.3.1 nerve cell original cuiture
Pregnant 15 days rat chloral hydrate anesthesias, 75% ethanol disinfection chest and abdomen take out tire mouse under aseptic condition, divide after stripping out
From both sides cortical tissue, rotten shape is cut into scalpel, is moved into containing digesting 30min in 0.125% tryptic phosphate buffer
Digestive juice is discarded after (37 DEG C), is added and is contained 10% hyclone, 10% horse serum, 100 μ/ml penicillin, 100 μ/ml streptomysins
DMED nutrient solutions, blow and beat dispersion repeatedly with small-bore suction pipe, after 200 mesh cell sieves are filtered, with DMEM adjustment cell concentration extremely
106/ml, in being seeded to the 35mm culture dishes for being pre-coated with relying poly- propylhomoserin 0.01%, per ware 2ml, putting 37 in CO2 incubators more
DEG C incubation, cell division inhibitor cylocide storing solution (6mm/ wares) is added on the 3rd day suppressing non-in culture in nutrient solution
The hyper-proliferative of neuronal cell, changes fresh medium after 48h, change liquid 2 times weekly later, half measures every time.
3.3.2NMDA receptor-inducible neural cell injury
Cell culture is randomly divided into blank control group, 50 μm of ol/L groups of NMDA, the μ of 6 administration group of embodiment 30 to after 14 days
Mol/L, embodiment 16 administration group, 50 μm of ol/L；Each group is changed with low serum DMEM (5% hyclone, 5% horse containing different pharmaceutical
Serum, 30mmol/LHEPES) continue to cultivate 6h, then add 50mmol/L NMDA, observation of cell form after incubation 12h calculates thin
Born of the same parents' death rate.Carry out statistical procedures.
3.4 result
3.4.1 to the impact of cultured nerve cell metamorphosis
Normal group Hemapoiesis are good, and cell space is tapered, fusiformis or triangle, cynapse is thick and grow, hand in tree root shape
It is made into net；NMDA tissue cultures are supported after 12h, and swelling, soft edge occurs in cell, and synapse fracture, disappearance, even cell collapse
Solution；Embodiment 6 and the administration group cellular damage degree of embodiment 16 substantially mitigate, and form keeps complete substantially, although embodiment 6 is given
The cell density of medicine group decreases, still the phenomenon such as visible cynapse fracture；Therefore, illustrate what this pharmaceutical composition was induced NMDA
Rat cellular damage has preferable protective effect.
3.4.2 to the impact of the cultured cells death rate
After NMDA groups incubation 12h, blue dyeing pigmented cells showed increased (the NMDA groups 79% of tongue phenol；Blank control group 10%,
P ＜ 0.001), point out cell mortality to increase；The administration group of embodiment 6, the administration group of embodiment 16 are respectively 38%, 20%, can be bright
It is aobvious to reduce cell mortality, compare that there were significant differences with NMDA groups.
4th, the clinical testing of medicine composite for curing ischemia-reperfusion injury of the present invention
4.1 trial drug：Embodiment 9, embodiment 10, preparation obtained in embodiment 14.
4.2 subjects：Healthy rat (body weight about 300g).
4.3 test method：
40 healthy adult rats are selected, 4 groups are divided at random, preoperative 6d fasting, free water use 10% chloraldurate
Intraperitoneal injection of anesthesia, dorsal position is fixed, and experimental group presses the dosed administration of 30mg/kg, and blank control group is not administered, after 30min,
In the positive median incision of neck, the total artery (CCA) of exposure right side of neck, external carotid artery (ECA) and arteria pterygopalatina, in arteria carotis communis crotch
Under cut longitudinal incision, with alcolhol burner the nylon wire (30, the U.S.) that round end is burnt till at two ends will be inserted into about 17- in internal carotid in advance
18mm, after blocking 2h county's bolt is extracted out, and blood is taken during Reperfu- sion 24h, and broken end takes brain, and the coronal brain piece for being cut to 0.3cm, observation whether there is
Blood stove.Brain piece is put in 10% formalin and is fixed, Jing after dehydration, soaking the steps such as cured, embedding, section, make the group of 8 μ m-thicks
Section is knitted, Toluidine blue staining carries out cell count with the brain piece penumbra region of same profile, and hypochromatosis, cell body secretly contaminate
As the index of neuronal necrosis, the percentage that downright bad neuron accounts for total neuron number is calculated.
4.4 result of the tests, as shown in table 4：
The neuronal necrosis percentage of table 4
Note：Administration group compares * P with control group<0.05, * * P<0.001
Conclusion：Blank control group neurons of rats peripheral clearance expands, and the dark dye neuron being dispersed in occurs, and nerve cell goes out
Now different degrees of shrinkage.Administration group has different degrees of mitigation, and the effect of the administration group of embodiment 14 is most strong, is secondly embodiment 9
Administration group.
5th, pharmaceutical composition of the present invention is to improving the test of learning and memory in rats
5.1 test article：
Invention formulation：Embodiment 7, embodiment 8, embodiment 11, preparation obtained in embodiment 14.
Reagent and instrument：Iibotenicacid (IBO)：Alexis companies of Switzerland produce, lot number LO5308；Rat brain is three-dimensional fixed
Position instrument (production of education experiment apparatus factory of Zhangjagang City)；Y types labyrinth, MG-3 labyrinths stimulator (Zhangjagang City's education experiment equipment
Factory).
5.2 subjects：Male SD rat (body weight about 200g).
5.3 test method：Take 60 rats and divide equally 6 groups, set up blank control group, modeling group and administration group, component is administered
Do not press dosed administration embodiment 7, embodiment 8, embodiment 11, the embodiment 14 of 30mg/kg；The daily feeding medicine for the treatment of group, mould
Type group and control rats are normal nursing, and after successive administration 20d learning and memory behavior is determined.
5.3.1AD animal modeling：After with 10% chloraldurate (0.4g/kg) intraperitoneal anesthesia, stereotaxic apparatus is fixed on
On；Conventional preserved skin sterilization, in the crown center sagital incision of a 1.5cm is done, with reference to rat brain stereotaxic atlas,
Meynert nuclear locations coordinate is (Ap：1.6mm Lat ± 2.8mm Dv.8.2mm), one is bored respectively in each corresponding points of bilateral skull
The hole of individual diameter 1mm, with glass microsyringe vertical injection is carried out.Treatment group bilateral Meynert cores are disposably noted per side
Penetrate BO5 μ g (with 1 μ l physiological saline solutions).Per pin injection time 5min, let the acupuncture needle remain at a certain point 10min makes BO fully spread.Control group is same
Method injects isometric physiological saline.Postoperative intramuscular injection penicillin prevention infection.
5.3.2 step down test：Self-control Jumping test case, bottom is covered with copper grid as stimulating electrode, and right lateral side is placed in case
One valve rubber escapes the place of safety of electric shock as rat.First it is put into rat and adapts to 5min, be subsequently passed 70V, 0.5A-0.7A is electric
Stream, normal reaction after rat is shocked by electricity is to jump onto platform to hide noxious stimulation.Record rat is from being initially powered up to complete
Appear on the stage the time used；Resurvey after 24h and test once to survey memory capability.
5.3.3Y maze test：Rat is put in Y types labyrinth and adapts to start experiment after 3min, have the support arm of light for not
Energization place of safety, after the bright 10s of place of safety lamp, another two-arm bottom alum gate is passed through 70V simultaneously, and 0.5A-0.7A electric currents, rat is shocked by electricity
Go to afterwards stop behind the place of safety of light, light continuation effect 30s, using the support arm at rat place as rising for testing next time
Point, random stochastic transformation place of safety.Place of safety is disposably run to as correct response with rat, is otherwise wrong reaction.Continuously
Test 30 times, record correct response number of times is used as school grade.Next day reforms carries out memory capability test.
5.4 result
The comparison of each group rat Jumping test and maze experiment learning and remembering ability, is shown in Table 5, table 6.Compared with control group
Modeling group ability of learning and memory has conspicuousness to decline, and illustrates that model is successfully established；Each treatment group compared with modeling group, learning ability
There is significant difference, illustrate that treatment is effective.
The Jumping test learning memory of table 5 compares
Note：Administration group compares * P with control group<0.05, * * P<0.001
The Y maze experiment learning memories of table 6 compare
Note：Administration group compares * P with control group<0.05, * * P<0.001
Conclusion：Alzheimer disease clinically first appears as the reduction of recent memory power, and continuation intelligence is presented then
Decline, wherein cognition dysfunction are its core symptom.By diving tower and Y maze tests, pharmaceutical composition pair of the present invention is observed
BO damages the impact of the cognitive functions such as the plan AD learning and memory in rats that bilateral NBM is caused, and as a result shows pharmaceutical composition of the present invention
The ability of learning and memory of rat can be improved, improve the disturbance of intelligence of Patients with Vascular Dementia.
6th, medicine composite for curing Prognosis of Acute Intracerebral Hemorrhage observation of curative effect of the present invention
6.1 enter group：Patients with cerebral hemorrhage 50, all meets inclusion criteria, average age about 60 years old.It is randomly divided into embodiment
14 administration groups and control group.Wherein administration group 25, male 15, female 10；Control group 25, man 13, female 12.Two groups sick
Example sex, the age, past medical history, be admitted to hospital when CT quantity of hematoma and Neuroscore in terms of no significant difference (P ＞
0.05), with comparativity.
6.2 test method：Control group gives and is dehydrated, drops cranium pressure, neurotrophy medicine, support to the ill, prevent infection, prevention
The conventional therapies such as complication, acupuncture and rehabilitation；Administration group in morbidity 24h, gives embodiment on the basis of control group
14 particulate matters, 3 times a day, a 6g, is used in conjunction 15d.With tada formula (quantity of hematoma=π/6 × major axis × short axle × aspect) calculating
Before patient's medication, the 15th day head CT volume of hematoma of medication.
6.3 criterion：Functional impairment scoring reduces 91%-100%；Marked improvement：Functional impairment scoring reduces 46%-
90%；It is progressive：Functional impairment scoring reduces 18%-45%；It is unchanged：Functional impairment scoring is reduced less than 17% or increased, and is wrapped
Include death.The 21st day before medication, after medication two groups of patients are carried out with neurological deficits score, and is judged according to scoring twice
Curative effect.
6.5 result
6.5.1 head CT quantity of hematoma, neurological deficits score compare head CT quantity of hematoma, nervous function before two groups of medications
Defect scores not statistically significant (P ＞ 0.05)；The 21st day after treatment group's medication, head CT quantity of hematoma, neurologic impairment are commented
Divide and significantly reduce (P ＜ 0.01).It is as shown in Table 7 below：
CT quantity of hematoma, neurological deficits score compare before and after 7 two groups of treatments of table
Note：Administration group compares * P with control group<0.05, * * P<0.001
6.5.2 clinical efficacy treatment group obvious effective rate (be almost recovered+marked improvement) is that total effective rate is；Control group is effective
Rate is that total effective rate is.Treatment group is significantly higher than control group (P ＜ 0.01).It is as shown in Table 8 below：
8 two groups of Clinical efficacy comparisons of table
| Group | It is almost recovered | Marked improvement | It is progressive | It is unchanged | It is total effective |
| Administration group | 5 | 9 | 9 | 2 | 23 |
| Control group | 1 | 7 | 10 | 7 | 18 |
Conclusion：It follows that pharmaceutical composition of the present invention can treat cerebral hemorrhage, accelerate absorption of hematoma, glue with blood is reduced
Degree, control encephaledema and mitigation nervous function ischemic lesions.
7th, safety testing
7.1 acute toxicity test
7.1.1 subjects：Healthy mice (body weight about 30g).
7.1.2 test method：Front fasting 16h is tested, not water restriction, dosage is 1mg/kg, observation 7 days, normally
Diet is drunk water.
7.1.3 observation index：Animal dead number.
7.1.4 result：Without dead mouse.
7.2 successive administration toxicity tests
7.2.1 subjects：Healthy mice (body weight about 20g).
7.2.2 test method：Healthy mice 50 is taken, 5 groups are divided at random, blank control group and administration group are set, its
In, administration group is given respectively with embodiment 1, embodiment 3, embodiment 4, the resulting composition of embodiment 5 by galenic pharmacy conventional method
Made by particulate matter, daily administration 2 times, each dosage is 2mg/kg, blank control group to equivalent physiological saline, continuously
Administration 20 days, observes 1 month, normal diet drinking-water.
7.2.3 observation index：Body weight increase situation, active situation, excrement situation, death condition.
7.2.4 result
Except administration 1 group of embodiment in addition to, other group without mouse poisoning, allergy a problem that, activity, diet drinking-water, excrement
Just situation is normal, and without death, but red swelling of the skin, vomiting and dysentery phenomenon occurs in 1 group of part of administration embodiment；Result of the test is such as
Shown in table 9：
The successive administration toxicity test result of table 9
Conclusion：Generally speaking, pharmaceutical composition security of the present invention is higher, has no toxic side effect.
8th, the test of the dizziness that medicine composite for curing VBI of the present invention causes
8.1 subjects：Healthy mice (body weight about 20g).
8.2 test drug：Preparation obtained in embodiment 14；Freeing granules, the production of Liaoning Jindan pharmaceutcal corporation, Ltd.
8.3 test method：Take 60 healthy mices, be at random 3 groups, i.e. blank control group, the administration group of embodiment 14 and
Freeing granules administration group；Before administration, using surgical ligation vertebral artery method, mouse vertebra substrate blood supply disorder is caused, then continuously given
Medicine 3 days, one time a day, each 2mg/kg, physiological saline of the blank control group to equivalent.
8.4 criterion of therapeutical effect：
8.4.1 it is effective：Dizziness and simultaneous phenomenon are wholly absent, and observation is not recurred for 12 hours.
8.4.2 effectively：Dizziness and cardinal symptom sign substantially mitigate.
8.4.3 it is invalid：Symptom is without improvement.
8.5 result：The administration group total effective rate of embodiment 14 is about 87.2%, and freeing granules administration group total effective rate is about
87.8%, two groups without difference, but control group symptom is without significant change, illustrates embodiment 14 and freeing granules to treatment
Dizziness has good therapeutic effect, therefore, pharmaceutical composition of the present invention can be applicable to the dizziness that VBI etc. causes.
Specific embodiment
It should be noted that this preparation embodiment is only a kind of method introduced extraction composition and prepare formulation,
It is to explain the present invention, rather than the restriction present invention.
The extraction of the pharmaceutical composition of embodiment 1
Formula：Coptis 290g, red stilbene 870g, glutinous rehmannia 870g, turmeric 800-864g, root of large-flowered skullcap 580g
Preparation method：60% ethanol heating and refluxing extraction of the coptis, turmeric three times is taken, for the first time immersion 1h, extract 1h, second,
Three extraction 50min, merge extract, filtration, and it is 1.00-1.05 (60 DEG C) that filtrate recycling ethanol third is concentrated into relative density,
It is standby；The dregs of a decoction add water to cook secondary, first time immersion 1h with red stilbene, glutinous rehmannia, decoct 1.3h, for the second time decoction 1h, collecting decoction,
Filtration, filtrate stands 24h, filtration, filtrate and the coptis, the merging of turmeric extract, is concentrated into relative density for 1.15-1.20 (60
DEG C) clear cream, filtration, filtrate adds Steviosin 15.38g, obtains the coptis, turmeric, red stilbene, the combined extracts of glutinous rehmannia；
Take the root of large-flowered skullcap secondary with 60% ethanol heating and refluxing extraction, for the first time immersion 1h, extract 2h, second extraction 1.6h,
Merge extract, filtration, filtrate recycling ethanol is simultaneously concentrated into the clear cream that relative density is 1.15-1.20 (60 DEG C), filtration, filtrate
Plus Steviosin 3.2g, obtain Baical Skullcap root P.E.
The extraction of the pharmaceutical composition of embodiment 2
Formula：Coptis 265g, red stilbene 795g, glutinous rehmannia 795g, turmeric 795g, root of large-flowered skullcap 530g
Preparation method：Composition is extracted according to the methods described of embodiment 1.
The extraction of the pharmaceutical composition of embodiment 3
Formula：Coptis 288g, red stilbene 864g, glutinous rehmannia 864g, turmeric 864g, root of large-flowered skullcap 576g are weighed, it is standby；
Preparation method：Composition is extracted according to the methods described of embodiment 1.
The extraction of the pharmaceutical composition of embodiment 4
Formula：Weigh coptis 270g, red stilbene 810g, glutinous rehmannia 810g, turmeric 810g, root of large-flowered skullcap 540g
Preparation method：Thing is combined according to the methods described of embodiment 1 to extract.
The extraction of the pharmaceutical composition of embodiment 5
Formula：Weigh coptis 277g, red stilbene 833g, glutinous rehmannia 833g, turmeric 833g, root of large-flowered skullcap 555g
Preparation method：Thing is combined according to the methods described of embodiment 1 to extract.
The preparation of preparation of embodiment 6
The composition extract that embodiment 1 is obtained, with galenic pharmacy routine techniques parenteral solution is prepared into.
The preparation of preparation of embodiment 7
The composition extract that embodiment 2 is obtained, with galenic pharmacy routine techniques pill is prepared into.
The preparation of preparation of embodiment 8
The composition extract that embodiment 3 is obtained, with galenic pharmacy routine techniques piece agent is prepared.
The preparation of preparation of embodiment 9
The composition extract that embodiment 4 is obtained, with galenic pharmacy routine techniques granule is prepared into.
The preparation of preparation of embodiment 10
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques piece agent is prepared.
The preparation of preparation of embodiment 11
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques capsule is prepared into.
The preparation of preparation of embodiment 12
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques oral liquid is prepared into.
The preparation of preparation of embodiment 13
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques pill is prepared into.
The preparation of preparation of embodiment 14
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques granule is prepared into.
The preparation of preparation of embodiment 15
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques injectable powder is prepared into.
The preparation of preparation of embodiment 16
The composition extract that embodiment 5 is obtained, with galenic pharmacy routine techniques water for injection injection is prepared into.
Claims (10)
1. application of a kind of pharmaceutical composition in treatment cerebrovascular drug is prepared, it is characterised in that：By weight, this is made
The raw material of pharmaceutical composition active principle is：The coptis (Miao：Wang Lian stems) 266-288 parts, red stilbene (Miao：Beans confuse) 800-864
Part, glutinous rehmannia (Miao：Fertile clatter) 800-864 parts, turmeric (Miao：Nest is breathed out) 800-864 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 532-576
Part.
2. a kind of pharmaceutical composition is preparing treatment Alzheimer's, improves the application in the medicine of memory, and its feature exists
In：By weight, the raw material for making the pharmaceutical composition active principle is：The coptis (Miao：Wang Lian stems) 266-288 parts, it is red
Stilbene (Miao：Beans confuse) 800-864 parts, glutinous rehmannia (Miao：Fertile clatter) 800-864 parts, turmeric (Miao：Nest is breathed out) 800-864 parts, the root of large-flowered skullcap
(Miao：Volume loud, high-pitched sound) 532-576 parts.
3. application of a kind of pharmaceutical composition in the medicine for preparing the dizziness that treatment vertebral-basilar artery insufficiency is caused, its
It is characterised by：By weight, the raw material for making the pharmaceutical composition active principle is：The coptis (Miao：Wang Lian stems) 266-288
Part, red stilbene (Miao：Beans confuse) 800-864 parts, glutinous rehmannia (Miao：Fertile clatter) 800-864 parts, turmeric (Miao：Nest is breathed out) 800-864
Part, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 532-576 parts.
4. application of the pharmaceutical composition as claimed in claim 1 in treatment cerebrovascular disease medicament is prepared, it is characterised in that：
The cranial vascular disease is：Ischemic cerebrovascular disease, hemorrhagic cerebrovascular disease.
5. application of the pharmaceutical composition as described in claim 1 or 4 in treatment cerebrovascular disease medicament is prepared, its feature exists
In：The cranial vascular disease is：Oedema after Prognosis of Acute Intracerebral Hemorrhage, cerebral ischemia, ischemic, cerebral ischemia/reperfusion injury, cerebral thrombus,
Infraction, nmda receptor induction cranial nerve cell are damaged.
6. the application as described in claim 1-3 is arbitrary, it is characterised in that：By weight, the pharmaceutical composition is made effective
The raw material of component is：The coptis (Miao：Wang Lian stems) 270-283 parts, red stilbene (Miao：Beans confuse) 810-849 parts, glutinous rehmannia (Miao：Fertilizer
Clatter) 810-849 parts, turmeric (Miao：Nest is breathed out) 810-849 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 540-566 parts.
7. the application as described in claim 1-3 is arbitrary, it is characterised in that：By weight, the pharmaceutical composition is made effective
The raw material of component is：The coptis (Miao：Wang Lian stems) 277 parts, red stilbene (Miao：Beans confuse) 833 parts, glutinous rehmannia (Miao：Fertile clatter) 833
Part, turmeric (Miao：Nest is breathed out) 833 parts, the root of large-flowered skullcap (Miao：Volume loud, high-pitched sound) 555 parts.
8. the application as described in claim 1-3 is arbitrary, it is characterised in that：Described pharmaceutical composition is according to following preparation methods
And obtain：
(1) coptis, turmeric, plus ethanol immersion, heating and refluxing extraction are taken, is merged, filtration, reclaim ethanol, concentration is standby；
(2) step 1 is taken) gained filter residue, decoct after soaking with red stilbene, glutinous rehmannia, merge, decocting liquid filtration, filtrate stands, filter
Cross, filtrate and step 1) gained liquid merges, is condensed into clear cream, filtration, and filtrate adds Steviosin, standby；
(3) root of large-flowered skullcap is taken, plus ethanol immersion, heating and refluxing extraction, merging, ethanol is reclaimed in extract filtration, is condensed into clear cream, is filtered
Cross, filtrate adds Steviosin, standby；
(4) said extracted thing is merged, is fully mixed, obtained final product.
9. the application as described in claim 1-3 is arbitrary, it is characterised in that：The medicine is ejection preparation, tablet, pill, glue
Wafer, granule, oral liquid, pill.
10. the application as described in claim 1-3 is arbitrary, it is characterised in that：The medicine is granule.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710104507.5A CN106581591A (en) | 2017-02-24 | 2017-02-24 | Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases |
| CN202010499986.7A CN111700995A (en) | 2017-02-24 | 2017-02-24 | Application of pharmaceutical composition in preparation of medicine for treating vertigo caused by vertebrobasilar artery insufficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710104507.5A CN106581591A (en) | 2017-02-24 | 2017-02-24 | Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010499986.7A Division CN111700995A (en) | 2017-02-24 | 2017-02-24 | Application of pharmaceutical composition in preparation of medicine for treating vertigo caused by vertebrobasilar artery insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581591A true CN106581591A (en) | 2017-04-26 |
Family
ID=58587922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710104507.5A Pending CN106581591A (en) | 2017-02-24 | 2017-02-24 | Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases |
| CN202010499986.7A Pending CN111700995A (en) | 2017-02-24 | 2017-02-24 | Application of pharmaceutical composition in preparation of medicine for treating vertigo caused by vertebrobasilar artery insufficiency |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010499986.7A Pending CN111700995A (en) | 2017-02-24 | 2017-02-24 | Application of pharmaceutical composition in preparation of medicine for treating vertigo caused by vertebrobasilar artery insufficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106581591A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975316A (en) * | 2021-10-09 | 2022-01-28 | 广西壮族自治区花红药业集团股份公司 | Application of radix puerariae, radix scutellariae and rhizoma coptidis composition in preparation of medicine for treating thrombus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813914B (en) * | 2012-09-12 | 2014-11-12 | 贵州神奇集团控股有限公司 | Medicinal composition used for treating or preventing cerebrovascular disease and related diseases |
| CN104644698B (en) * | 2015-02-06 | 2018-05-11 | 贵州神奇药物研究院 | A kind of product for preventing senile dementia and preparation method thereof |
-
2017
- 2017-02-24 CN CN201710104507.5A patent/CN106581591A/en active Pending
- 2017-02-24 CN CN202010499986.7A patent/CN111700995A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 万海同主编: "《中西医结合脑血管病临床与科研方法》", 31 January 2015, 中国中医药出版社 * |
| 南京中医药大学编著: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 国家药典委员会编: "《中华人民共和国药典2015年版 第一部》", 30 June 2015, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975316A (en) * | 2021-10-09 | 2022-01-28 | 广西壮族自治区花红药业集团股份公司 | Application of radix puerariae, radix scutellariae and rhizoma coptidis composition in preparation of medicine for treating thrombus |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111700995A (en) | 2020-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104547486A (en) | Traditional Chinese medicine preparation for treating anemia and qi-deficiency weakness and preparation process for traditional Chinese medicine preparation | |
| CN103405742A (en) | Drug composition for treating infantile diarrhea and preparation method thereof | |
| CN104491733A (en) | Application of traditional Chinese medicine preparation in preparation of medicines for treating anemia, deficiency of vital energy and debilitation | |
| CN104524106A (en) | Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN104352793A (en) | Traditional Chinese medicine preparation for treating gastrointestinal bleeding and preparation method thereof | |
| CN115350256B (en) | Traditional Chinese medicine composition for treating insomnia and preparation method thereof | |
| CN106581591A (en) | Application of drug composition in preparation of drugs for treating cerebrovascular disease or relevant diseases | |
| CN104645124A (en) | Traditional Chinese medicine preparation for treating lithangiuria and preparation method thereof | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN105169279A (en) | Traditional Chinese medicine composition for treating knee joint bone hyperplasia | |
| CN104857370A (en) | Traditional Chinese medicine composition for treating breast cancer | |
| CN104324135A (en) | Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition | |
| CN100409852C (en) | Chinese medicine for enhancing immunologic function | |
| CN104352994A (en) | Pharmaceutical preparation for sexual dysfunction | |
| CN108578649A (en) | The Chinese medicine and preparation method and application for the treatment of encephalatrophy, senile dementia and cerebral infarction | |
| CN109432364A (en) | The female Chinese medicine composition of ginseng stilbene benefit and the preparation method and application thereof for Recovery | |
| CN104257871B (en) | Scorching pharmaceutical composition of the acute lymphatic meshwork of type and preparation method thereof is accumulate for treating damp and hot poison | |
| CN102961704A (en) | Pharmaceutical composition for treating liver caner and method for preparing dispersible tablets thereof | |
| CN107898990A (en) | A kind of Chinese medicine preparation for treating neurosis and preparation method thereof | |
| CN106039194A (en) | Composite preparation for treating leucopenia caused by radiotherapy and chemotherapy | |
| CN102091181A (en) | Chinese medicinal composition for treating acute and chronic granulocytic leukemia 1 and preparation method thereof | |
| CN105831751A (en) | Health-care traditional Chinese medicine composition with effects of tonifying qi and strengthening brain and preparation method and using method thereof | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN104840814A (en) | Traditional Chinese medicine combination for treating senile femoral head necrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |